合成生物 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROMTO Commission File Number 001-37566 SYNLOGIC, INC. 26-1824804(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) Securities registered pursuant to Section 12(b) of the Act:None Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerginggrowth company" in Rule 12b–2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☒No☐ As of August 4, 2026, there were 12,248,950shares of the registrant’s common stock, par value $0.001 per share, outstanding. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make suchforward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and otherfederal securities laws. All statements other than statements of historical facts contained herein are forward-looking statements. Insome cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,”“plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or othercomparable terminology. These forward-looking statements include, but are not limited to, statements about: •our forthcoming merger with Caldera Therapeutics, Inc. and the parties’ ability to consummate and realize the benefitsof such merger;•the price for shares of our common stock given that they are currently quoted on the OTCID Basic Market and mayexperience limited trading;•the terms and timing of any additional collaborative, licensing or other arrangements that we may establish;•the acquisition of businesses, products and technologies;•our need to implement additional infrastructure and internal systems; and•other risks and uncertainties, including those listed under Part II, Item 1A. “Risk Factors.” Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future eventsor to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ouractual results, performance or achievements to be materially different from any future results, performance or achievementsexpressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from currentexpectations include, among other things, those listed in the “Risk Factors” section contained in our Annual Report on Form 10-Kfor the fiscal year ended December 31, 2025 (the 2025 Annual Report), filed with the Securities and Exchange Commission (theSEC) on March 12, 2026 and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not placeundue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise theseforward-looking statements for any reason, even if new information becomes available in the future. This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, ourbusiness, and the markets for certain diseases, including data regarding the incidence and prevalence of certain medical conditions.Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject touncertainti